Cyrus Harmon - 18 Jun 2021 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
CHIEF TECHNOLOGY OFFICER, Director
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
18 Jun 2021
Transactions value $
-$297,626
Form type
4
Filing time
21 Jun 2021, 19:05:36 UTC
Next filing
21 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$230,921 -9,410 -0.85% $24.54 1,102,136 18 Jun 2021 Direct F1, F2
transaction OLMA Common Stock Sale -$50,924 -1,990 -0.18% $25.59 1,100,146 18 Jun 2021 Direct F1, F3
transaction OLMA Common Stock Sale -$15,780 -600 -0.05% $26.3 1,099,546 18 Jun 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2 The weighted average sale price for the transaction reported was $24.54, and the range of prices were between $24.18 and $25.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $25.59, and the range of prices were between $25.16 and $26.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 2. The weighted average sale price for the transaction reported was $26.30, and the range of prices were between $26.19 and $26.99. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.